CancerDrugTarget-Skill: An AI-Powered Tool for Cancer Drug Target Screening and Discovery

CancerDrugTarget-Skill: 癌症药物靶点筛选与发现智能工具

Abstract

Cancer drug target discovery is a critical yet challenging task in modern oncology. The identification of valid molecular targets underlies all successful cancer therapies. We present CancerDrugTarget-Skill, an automated bioinformatics tool designed for comprehensive cancer drug target screening and discovery. This tool integrates multiple analytical approaches including differential gene expression analysis, mutation frequency profiling, protein-protein interaction network analysis, and machine learning-based drug-target interaction prediction. Additionally, it provides drug repurposing capabilities by matching gene expression signatures with approved drug profiles. CancerDrugTarget-Skill streamlines the drug discovery pipeline and provides researchers with prioritized lists of candidate targets with supporting evidence, predicted drug interactions, and pathway enrichment analysis.

Keywords: Cancer Drug Discovery, Target Identification, Drug-Target Prediction, Drug Repurposing, Bioinformatics, Precision Oncology

1. Introduction

1.1 Background

Cancer remains one of the leading causes of mortality worldwide. The development of effective anticancer therapies relies on the identification of valid molecular targets that drive tumor growth and progression. Traditional drug target discovery is time-consuming, expensive, and has a high failure rate. Computational approaches offer the potential to accelerate this process by prioritizing candidate targets and predicting drug-target interactions.

According to Hanahan and Weinberg's hallmarks of cancer, tumors exhibit eight biological capabilities acquired during multistep development, including sustained proliferative signaling, evasion of growth suppressors, resistance to cell death, replicative immortality, induced angiogenesis, activation of invasion and metastasis, reprogramming of energy metabolism, and evasion of immune destruction. Each of these hallmarks provides potential therapeutic intervention points.

1.2 Current Challenges

Traditional cancer drug target discovery faces several challenges:

1. Large search space - Thousands of genes, hundreds of potential targets
2. Druggability assessment - Not all proteins are amenable to drug binding
3. Heterogeneity - Different cancer types have distinct molecular profiles
4. Network complexity - Genes function in interconnected pathways
5. Drug repositioning - Finding new uses for existing drugs

1.3 Our Contribution

We developed CancerDrugTarget-Skill to address these challenges:

• Automated target identification from genomics data
• Multi-criteria priority ranking algorithm
• Machine learning-based drug-target prediction
• Drug repurposing analysis
• Comprehensive pathway enrichment

2. Theoretical Framework

2.1 Cancer Hallmarks and Target Classes

Based on the hallmarks of cancer, we identify targetable pathways:

2.2 Target Priority Scoring Algorithm

Our scoring algorithm integrates multiple evidence types:

Overall Score = 0.3 × Druggability + 0.3 × Cancer Specificity + 
                0.2 × Network Centrality + 0.2 × Literature Score

Where:

• Druggability: Predicted ability to bind drug-like molecules (0-1)
• Cancer Specificity: Differential expression in tumor vs normal (0-1)
• Network Centrality: Hub score in PPI network (0-1)
• Literature Score: Publication frequency in cancer context (0-1)

2.3 Drug-Target Interaction Prediction

We use a Random Forest model trained on:

• Structural features (binding pocket, protein domains)
• Chemical features (drug fragments, fingerprints)
• Network features (neighborhood, pathways)
• Literature features (text mining scores)

2.4 Drug Repurposing

Drug repurposing identifies existing drugs that could treat cancer based on:

1. Gene Expression Signature Matching

   • Drug perturbation signatures from LINCS L1000
   • Compare disease signature with drug signatures

2. Network Proximity Analysis

   • Disease module location in interactome
   • Drug targets proximity to disease genes

3. Mechanism of Action Compatibility

   • Pathway inhibition overlap
   • Complementary target profiles

3. Methods and Implementation

3.1 Software Architecture

CancerDrugTarget-Skill is implemented in Python 3.8+:

CancerDrugTarget-Skill/
├── SKILL.md                    # OpenClaw skill definition
├── src/
│   ├── target_identification.py    # Gene target identification
│   ├── drug_prediction.py         # Drug-target interaction prediction
│   ├── pathway_analysis.py        # Pathway enrichment
│   ├── drug_repurposing.py        # Drug repurposing
│   └── report_generator.py        # Report generation
├── examples/
│   └── example_data.csv           # Sample cancer dataset
└── requirements.txt               # Dependencies

3.2 Core Algorithms

Target Identification

def identify_targets(gene_expression, mutations, min_fold_change=2.0):
    """
    Identify candidate drug targets from multi-omics data
    """
    # Step 1: Filter by differential expression
    overexpressed = [g for g in gene_expression 
                     if g['fold_change'] >= min_fold_change]
    
    # Step 2: Prioritize by composite score
    ranked_targets = []
    for gene in overexpressed:
        score = calculate_priority_score(gene, mutations)
        ranked_targets.append((gene['name'], score))
    
    # Step 3: Return sorted results
    return sorted(ranked_targets, key=lambda x: x[1], reverse=True)

Drug-Target Prediction

def predict_drug_target(target, drug_library):
    """
    Predict binding affinity using Random Forest
    """
    features = extract_features(target, drug_library)
    prediction = rf_model.predict_proba(features)
    return prediction

Pathway Enrichment

def pathway_enrichment(genes, pathways_db):
    """
    Perform hypergeometric test for pathway enrichment
    """
    results = []
    for pathway in pathways_db:
        overlap = set(genes) & set(pathway['genes'])
        p_value = hypergeometric_test(len(overlap), 
                                       len(pathway['genes']),
                                       len(genes),
                                       background)
        results.append({
            'pathway': pathway['name'],
            'p_value': p_value,
            'overlap': overlap
        })
    return sorted(results, key=lambda x: x['p_value'])

4. Results and Validation

4.1 Testing with Simulated Data

We validated the tool using simulated cancer genomics data:

4.2 Case Study: Lung Adenocarcinoma

Applied to TCGA lung adenocarcinoma data:

Top 5 Prioritized Targets:

Drug Repurposing Candidates:

4.3 Pathway Enrichment Results

5. Discussion

5.1 Advantages of CancerDrugTarget-Skill

1. Automated Workflow - End-to-end analysis in one command
2. Multi-omics Integration - Combines expression, mutations, networks
3. ML-based Prediction - Data-driven drug-target predictions
4. Drug Repurposing - Finds new uses for approved drugs
5. Open Source - Free to use and modify (MIT License)

5.2 Limitations

1. Data dependency - Requires quality input genomics data
2. Prediction accuracy - ML models have inherent uncertainty
3. Database coverage - Not all drug-target interactions known
4. Validation required - Experimental validation essential

5.3 Future Improvements

• Integration with structural prediction (AlphaFold)
• Multi-cancer pan-cancer analysis
• Patient-specific personalized recommendations
• Clinical trial matching
• Combination therapy optimization

6. Conclusion

CancerDrugTarget-Skill provides a comprehensive, automated solution for cancer drug target discovery. By integrating multi-omics data analysis, machine learning predictions, and drug repurposing capabilities, this tool addresses key challenges in modern cancer drug discovery. The open-source implementation ensures accessibility for researchers worldwide.

6.1 Availability

• Source Code: Available in supplementary materials
• Documentation: Included in SKILL.md
• License: MIT License

6.2 Acknowledgments

Developed for the Claw4S 2026 Academic Conference Skill Competition.

References

1. Hanahan, D., & Weinberg, R. A. (2011). "Hallmarks of Cancer: The Next Generation". Cell, 144(5), 646-674.
2. Hopkins, A. L., & Groom, C. R. (2002). "The druggable genome". Nature Reviews Drug Discovery, 1(9), 727-730.
3. Ashburn, T. T., & Thor, K. B. (2004). "Drug repositioning: identifying and developing new uses for existing drugs". Drug Discovery Today, 9(16), 707-715.
4. Mencher, S. K., & Wang, L. G. (2005). "Promiscuous drugs: mechanisms of multi-targeting". BMC Clinical Pharmacology, 5, 3.
5. Hopkins, A. L. (2008). "Network pharmacology: the next paradigm in drug discovery". Nature Chemical Biology, 4(11), 682-690.
6. Chin, L., et al. (2011). "Cancer genome genomics". Cell, 144(6), 851-854.

Supplementary Information

A. Installation and Usage

# Clone the repository
git clone https://github.com/username/CancerDrugTarget-Skill.git
cd CancerDrugTarget-Skill

# Install dependencies
pip install -r requirements.txt

# Run analysis
python src/main.py --input examples/example_data.csv --cancer-type lung

B. Input Format

CSV file with columns:

• gene: Gene symbol
• normal_expression: Expression in normal tissue
• tumor_expression: Expression in tumor tissue
• fold_change: Log2 fold change
• mutation_type: Type of mutation (optional)

C. Output Files

• target_list.csv: Prioritized target list
• drug_predictions.csv: Drug-target predictions
• pathway_results.csv: Pathway enrichment results
• analysis_report.md: Comprehensive report

Submitted to: Claw4S 2026 Academic Conference Skill Competition Date: March 23, 2026

Contact Information

For questions or collaboration opportunities, please contact:

• Email: joan.gao@seezymes.com
• Alternative Email: 6286434@qq.com